Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
LXRX · Why this verdict
Why Lexicon Pharmaceuticals (LXRX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Lexicon Pharmaceuticals combines value-trap warning signs (declining revenue, cash burn, high leverage) with a bullish technical breakout and a strong EPS beat streak, leaving a fundamentally weak but technically momentum-driven setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Lexicon shows 3 of 5 classic value-trap signals: revenue declining 33.1% YoY, operating margin compressed to -27.2%, and leverage at 7.2x debt-to-equity. Bear case | Revenue growth should turn positive YoY to disprove the value-trap read. | ↑Improving |
| CounterThe quality score's Rule-of-40 notation flags an elite combined growth-plus-margin reading, suggesting offsetting strength elsewhere in the business. | ||
Lexicon is burning cash at a rate equal to 41% of revenue, raising questions about runway without additional financing. Quality breakdown | Free cash flow as a percentage of revenue should improve within the next few quarters. | →Stable |
| CounterStrong analyst-implied upside of 63% suggests the market believes near-term pipeline or product catalysts will offset the cash burn. | ||
Lexicon has formed a technical breakout, a golden cross with price above all major moving averages and a bullish MACD reading, even as fundamentals remain weak. Chart pattern detection | Price should hold above its 200-day moving average and the breakout setup should persist. | Tripped→Stable |
| CounterRSI near 69 is approaching overbought territory, and momentum can reverse quickly in a stock with weak underlying quality metrics. | ||
Lexicon has beaten EPS estimates in 3 of its last 4 reported quarters, with an average surprise of about 74%, suggesting consistent execution against a conservative consensus bar. Earnings | The beat streak should continue at the next print. | →Stable |
| CounterReported EPS is still negative in absolute terms, so the beats reflect smaller-than-expected losses rather than actual profitability. | ||
Short interest of 11% of float combined with an elevated put/call ratio of 6.67 signals the options market is heavily positioned for downside. Key risks | The put/call ratio should fall back toward more typical levels. | ↑Improving |
| CounterHigh short interest can also fuel a short squeeze if a positive catalyst hits a heavily shorted, thinly covered biotech. | ||
Lexicon shows 3 of 5 classic value-trap signals: revenue declining 33.1% YoY, operating margin compressed to -27.2%, and leverage at 7.2x debt-to-equity.
↑ImprovingBear case
- Expectation
- Revenue growth should turn positive YoY to disprove the value-trap read.
CounterThe quality score's Rule-of-40 notation flags an elite combined growth-plus-margin reading, suggesting offsetting strength elsewhere in the business.
Lexicon is burning cash at a rate equal to 41% of revenue, raising questions about runway without additional financing.
→StableQuality breakdown
- Expectation
- Free cash flow as a percentage of revenue should improve within the next few quarters.
CounterStrong analyst-implied upside of 63% suggests the market believes near-term pipeline or product catalysts will offset the cash burn.
Lexicon has formed a technical breakout, a golden cross with price above all major moving averages and a bullish MACD reading, even as fundamentals remain weak.
Tripped→StableChart pattern detection
- Expectation
- Price should hold above its 200-day moving average and the breakout setup should persist.
CounterRSI near 69 is approaching overbought territory, and momentum can reverse quickly in a stock with weak underlying quality metrics.
Lexicon has beaten EPS estimates in 3 of its last 4 reported quarters, with an average surprise of about 74%, suggesting consistent execution against a conservative consensus bar.
→StableEarnings
- Expectation
- The beat streak should continue at the next print.
CounterReported EPS is still negative in absolute terms, so the beats reflect smaller-than-expected losses rather than actual profitability.
Short interest of 11% of float combined with an elevated put/call ratio of 6.67 signals the options market is heavily positioned for downside.
↑ImprovingKey risks
- Expectation
- The put/call ratio should fall back toward more typical levels.
CounterHigh short interest can also fuel a short squeeze if a positive catalyst hits a heavily shorted, thinly covered biotech.
Per-dimension breakdown
Quality
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -108% of revenue
- ▸No competitive moat
- ▸Rule of 40: -206 (fail)
Growth
5.0/10data confidence 50%Momentum
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 6.1 |
| OBV | 10.0 |
| MA position | 2.2 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+4.0%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.5 |
| Analyst rating | 6.6 |
| Price target | 10.0 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 195%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
1.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.4 |
| quality rank | 1.8 |
| growth rank | 0.0 |
Technical
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.9 |
| support resistance | 7.0 |
| 52w position | 1.3 |
| gap | 5.0 |
Risk (lower is worse)
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.3 |
| days to cover | 1.6 |
| volatility | 0.0 |
| put call | 10.0 |
| beta | 6.7 |
| debt equity | 8.6 |
- ▸Concentration risks: 3 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 6.0 |
- ▸Earnings in 6 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- ASYMMETRY:14.5>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:4.4<4.5
- EARNINGS_PROXIMITY:6d<=7d
Warning (0)
none
Reward-to-Risk
14.46
Upside
+156.4%
Downside
10.8%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -44% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 4.4<4.5 outcome against Sentiment at 7.3 and asymmetric R:R of 14.46.
The strongest dimensions are Sentiment at 7.3, Insider at 7.3, and Catalyst at 7.2; the weakest are Peer rank at 1.9, Quality at 3.4, and Momentum at 4.4. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 14.46 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Value Trap Revenue Decline
Trip ifRevenue growth rises above 0% YoY, reversing the current -33.1% decline.
- P2Cash Burn Runway Risk
Trip ifFree cash flow rises above -20% of revenue from the current -41%.
- P3Technical Breakout SetupTripped
Trip ifPrice falls below the 200-day moving average, breaking the current technical setup.
- P4Earnings Beat Streak
Trip ifEPS surprise falls below 0% (a miss) at the next earnings print.
- P5Elevated Bearish Positioning
Trip ifPut/call ratio falls below 2.0 from the current 6.67.